Panbela Therapeutics, Inc.
PBLA
$0.2603
-$0.0607-18.91%
OTC PK
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.63% | -8.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.58% | 20.47% | |||
| Operating Income | 11.58% | -20.47% | |||
| Income Before Tax | -0.46% | 1.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.46% | -0.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.46% | -0.27% | |||
| EBIT | 11.58% | -20.47% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -0.46% | 35.44% | |||
| Normalized Basic EPS | 9.37% | 29.80% | |||
| EPS Diluted | -0.46% | 35.44% | |||
| Normalized Diluted EPS | 9.37% | 29.80% | |||
| Average Basic Shares Outstanding | 0.00% | 55.32% | |||
| Average Diluted Shares Outstanding | 0.00% | 55.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||